Lilly Projects 2024 Revenue Miss as Zepbound, Mounjaro Disappoint
The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, sent Eli Lilly’s shares cratering by as much as 8% Tuesday, even as the company forecasted robust 2025 revenue.
In a live taping of "The Readout LOUD" at #JPM25, Eli Lilly CEO Dave Ricks talks Trump, Medicare's drug price negotiation, ...
People claim the viral "natural Mounjaro" drink — honey, lemon, water, and ginger — makes you lose weight. Here's what an ...
24/7 Wall St. on MSN5h
Down 23%, Is This Dividend Giant a Buy After GLP-1 Sales Miss?Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...
Research reveals groundbreaking results about Mounjaro and Ozempic in weight loss treatment. Here's what you need to know ...
19dOpinion
No one has ever known so much about healthy eating and been less successful at following her own advice.
Up to 3.4 million eligible patients could benefit from the medication that treats type 2 diabetes and aids weight loss ...
Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.
Eli Lilly has revised its revenue forecast for 2024 after seeing weaker-than-expected growth for its diabetes and obesity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback